华夏恒生生科(03069)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

03069 华夏恒生生科

已收盘 09-14 16:08:04

15.590

+0.610

+4.07%

最高15.650	最低14.880	成交量480.98万
今开14.980	昨收14.980	日振幅5.14%
总市值24.61亿	流通市值24.61亿	总股本1.58亿
成交额7,335万	换手率3.05%	流通股本1.58亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"03069","market":"HK","secType":"STK","nameCN":"华夏恒生生科","latestPrice":15.59,"timestamp":1789373284006,"preClose":14.98,"halted":0,"volume":4809800,"delay":0,"changeRate":0.040720961281708906,"floatShares":157860531,"shares":157860531,"eps":0,"marketStatus":"已收盘","change":0.61,"latestTime":"09-14 16:08:04","open":14.98,"high":15.65,"low":14.88,"amount":73352792,"amplitude":0.051402,"askPrice":15.59,"askSize":1300,"bidPrice":15.58,"bidSize":1400,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789435800000},"marketStatusCode":5,"adr":0,"listingDate":1615996800000,"exchange":"SEHK","adjPreClose":14.98,"sharesOutstanding":237400000,"nav":15.0694,"aum":0,"dividendRate":0.003207,"bidAskSpread":0,"openAndCloseTimeList":[[1789349400000,1789358400000],[1789362000000,1789372800000]],"volumeRatio":1.470831,"lotSize":100,"spreadScale":3,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/03069/wiki","defaultTab":"wiki","newsList":[{"id":"2667554366","title":"ETF异动 | 华夏恒生生科(03069)涨超4% WCLC临床数据催化密集 机构看好创新药投资机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2667554366","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667554366?lang=zh_cn&edition=full","pubTime":"2026-09-14 15:17","pubTimestamp":1789370250,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，华夏恒生生科涨超4%。截至发稿，涨4.01%，报15.58港元，成交额6924.78万港元。本次WCLC会议上，中国新药表现亮眼，入选口头报告研究19项，小型口头报告研究45项，刷新记录。国金证券称，创新药企业扭亏节点到来，全年临床数据催化密集，叠加已BD出海管线海外临床进展顺利，看好创新药板块投资机会。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495572.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4550","03069","IBBQ","BK1574","BK4585","06978","159992","MEDX","FDN","BK4588","BK1161","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667003455","title":"每周股票复盘：中国医药（600056）获业绩补偿款10,120.95万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2667003455","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667003455?lang=zh_cn&edition=full","pubTime":"2026-09-13 03:00","pubTimestamp":1789239631,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘，中国医药报收于8.91元，较上周的9.06元下跌1.66%。本周，中国医药9月8日盘中最高价报9.18元。本周关注点公司公告汇总：中国医药收到业绩补偿款本息合计10,120.95万元。公司公告汇总中国医药健康产业股份有限公司于2026年9月7日召开第十届董事会第7次会议，审议通过聘任张琳女士为公司董事会秘书，任期自董事会决议通过之日起至第十届董事会届满。案件判决已生效并进入执行阶段，涉案金额为13,940.41万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091300000865.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","600056","BK0175","BK0082","BK0188","03069","BK0010","BK0028","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666540384","title":"智飞生物：专一、专注、专业地在生物制药领域深耕","url":"https://stock-news.laohu8.com/highlight/detail?id=2666540384","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666540384?lang=zh_cn&edition=full","pubTime":"2026-09-11 16:57","pubTimestamp":1789117034,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)09月11日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，现在投资者很多都已经盼望智飞生物直接退市，本金早已经亏损完了，对公司发展更不抱有任何希望。公司针对这一现实情况，公司的市值管理计划是怎样实施的？效果怎样？请详细回答一下，谢谢。智飞生物回复：您好，公司专一、专注、专业地在生物制药领域深耕，聚焦生产经营稳健发展，持续开展产品创新，巩固核心竞争力；优化市场营销策略，提升商业推广效能；同时完善治理体系，强化全过程质量管理，为企业长远发展奠定坚实基础。感谢关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091100036450.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","LU2580892862.HKD","03069","LU1064130708.USD","BK0188","LU1328615791.USD","300122","BK0196","LU2148510915.USD","LU2580892789.USD","BK0046","BK0239","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666997515","title":"股市必读：派林生物新发布《北京市嘉源律师事务所关于派斯双林生物制药股份有限公司2026年第三次临时股东会的法律意见书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2666997515","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666997515?lang=zh_cn&edition=full","pubTime":"2026-09-11 03:54","pubTimestamp":1789070077,"startTime":"0","endTime":"0","summary":"公司公告汇总北京市嘉源律师事务所关于派斯双林生物制药股份有限公司2026年第三次临时股东会的法律意见书北京市嘉源律师事务所对派斯双林生物制药股份有限公司2026年第三次临时股东会的召集、召开程序、出席会议人员资格、召集人资格、表决程序及表决结果进行了见证。会议召集、召开程序及表决结果合法有效，北京市嘉源律师事务所出具了法律意见书。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091100011605.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000403","BK0239","03069","BK0071"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665032189","title":"中国医药（600056）披露聘任董事会秘书公告，9月8日股价上涨1.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2665032189","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665032189?lang=zh_cn&edition=full","pubTime":"2026-09-08 17:57","pubTimestamp":1788861455,"startTime":"0","endTime":"0","summary":"截至2026年9月8日收盘，中国医药报收于9.17元，较前一交易日上涨1.33%，最新总市值为137.17亿元。中国医药健康产业股份有限公司于2026年9月7日召开第十届董事会第7次会议，审议通过聘任张琳女士为公司董事会秘书，任期自董事会决议通过之日起至第十届董事会届满。公司已就本次聘任向上海证券交易所完成备案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090800028222.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0082","BK0175","BK0010","BK0250","BK0185","03069","600056","BK0188","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665395840","title":"里昂：中国生物科技基本面仍稳固 首选百济神州(06160.HK)、信达生物(01801.HK)及维立志博(09887.HK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2665395840","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665395840?lang=zh_cn&edition=full","pubTime":"2026-09-07 09:52","pubTimestamp":1788745948,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06160","KURE","LU0307460666.USD","LU2097828557.USD","LU2097828631.EUR","HK0000252160.HKD","LU0228659784.USD","LU2097828714.EUR","LU0326950275.SGD","LU2242644610.SGD","BK1583","LU2097828805.USD","LU1770034418.SGD","LU1719994722.HKD","LU0588546209.SGD","LU1251922891.USD","LU1303224171.USD","LU1969619763.USD","LU0463099449.HKD","BK1589","LU0828237510.HKD","HK0000165453.HKD","01801","LU0244354667.USD","BK1161","LU1188198961.HKD","03069","LU2328871848.SGD","BK1500","09887","LU2488822045.USD","LU0502904849.HKD","HK0000252152.HKD","LU0455707207.USD","BK1588","HK0000500386.USD","LU2097828474.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665366324","title":"每周股票复盘：中国医药（600056）董秘变更由董事长代行职责","url":"https://stock-news.laohu8.com/highlight/detail?id=2665366324","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665366324?lang=zh_cn&edition=full","pubTime":"2026-09-06 03:14","pubTimestamp":1788635652,"startTime":"0","endTime":"0","summary":"截至2026年9月4日收盘，中国医药报收于9.06元，较上周的9.28元下跌2.37%。本周，中国医药8月31日盘中最高价报9.27元。本周关注点公司公告汇总：董事会秘书袁精华因工作调整辞职，辞职后继续担任公司副总经济师，由董事长代行董事会秘书职责。其辞职自送达董事会之日起生效。截至公告日，袁精华先生未持有公司股票，不存在未履行完毕的公开承诺。公司董事会对袁精华先生在任职期间所作贡献表示感谢。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090600001052.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0185","BK0250","BK0028","BK0082","600056","BK0175","BK0010","03069"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665936888","title":"复宏汉霖朱俊：未来所有制药企业都是AI制药企业，不存在不依赖AI的生物制药企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2665936888","media":"睿见Economy","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665936888?lang=zh_cn&edition=full","pubTime":"2026-09-05 14:04","pubTimestamp":1788588240,"startTime":"0","endTime":"0","summary":"朱俊坦言，尽管近年来国家批准的创新药数量已领先全球，但临床疗效的提升依然艰难。他强调，如果AI不能进一步赋能，生物医药产业将继续处于原始状态。未来，所有的制药企业都必须是AI制药企业，不存在不依赖AI的生物制药企业。朱俊总认为，在全球变局下，只要企业能够用好AI、抓住精准人群并解决真实的临床痛点，即使十个机会中只能抓住一个，也足以支撑企业的长远发展。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/hy/hyjz/2026-09-05/doc-iniquccs3668085.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["AIPO","ARTY","HK0000320264.USD","AGIX","MRNX","HK0000306701.USD","BK1574","VTHR","03069","01477","HK0000306685.HKD","BK1161","IBBQ","QTOC","02696","MRNY","CHAT","HK0000320223.HKD","BBP","HK0000165453.HKD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664337721","title":"康宁杰瑞生物制药回购56,000股 耗资492,430港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2664337721","media":"财闻","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664337721?lang=zh_cn&edition=full","pubTime":"2026-09-04 20:53","pubTimestamp":1788526380,"startTime":"0","endTime":"0","summary":"9月4日，康宁杰瑞生物制药于2026年9月4日在香港联交所回购56,000股普通股，每股回购价格最高HKD8.8、最低HKD8.75，付出价格总额HKD492,430。回购股份拟持作库存股份，拟注销数目为0。回购后，已发行股份数目由968,056,697股减至968,000,697股，库存股份数目由6,325,000股增至6,381,000股，已发行股份总数维持974,381,697股。此次回购依据2026年6月12日获通过的回购授权进行，该授权可回购股份总数为96,850,669股。回购后暂止期截至2026年10月4日。呈交者为执行董事徐霆。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-09-04/doc-iniqsrak4001786.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["MRNY","BBP","CNAV","IBBQ","MRNX","03069","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664456128","title":"股市必读：中国医药新发布《关于董事会秘书离任的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2664456128","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664456128?lang=zh_cn&edition=full","pubTime":"2026-09-03 02:01","pubTimestamp":1788372080,"startTime":"0","endTime":"0","summary":"公司公告汇总关于董事会秘书离任的公告中国医药董事会于2026年9月1日收到董事会秘书袁精华的书面辞职函，其因工作调整申请辞去该职务，辞职自送达董事会之日起生效；辞职后袁精华继续担任公司副总经济师；截至公告日，其未持有公司股票，无未履行完毕的公开承诺；董事会秘书空缺期间，由公司董事长代行相关职责。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090300001902.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0082","03069","600056","BK0010","BK0175","BK0028","BK0188","BK0185","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664857989","title":"中国医药（600056）披露董事会秘书离任公告，9月1日股价上涨0.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664857989","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664857989?lang=zh_cn&edition=full","pubTime":"2026-09-01 22:42","pubTimestamp":1788273740,"startTime":"0","endTime":"0","summary":"近日，中国医药健康产业股份有限公司发布《关于董事会秘书离任的公告》。公告显示，公司董事会于2026年9月1日收到董事会秘书袁精华先生的书面辞职函，因工作调整原因，袁精华先生申请辞去公司董事会秘书职务，辞职后将继续担任公司副总经济师。其辞职自送达董事会之日起生效。截至公告日，袁精华先生未持有公司股票，不存在未履行完毕的公开承诺。公司董事会对袁精华先生在任职期间所作贡献表示感谢。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090100043251.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600056","BK0188","BK0028","BK0185","03069","BK0175","BK0082","BK0250","BK0010"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664882099","title":"中国医药步入黄金时代","url":"https://stock-news.laohu8.com/highlight/detail?id=2664882099","media":"证券市场周刊","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664882099?lang=zh_cn&edition=full","pubTime":"2026-09-01 10:16","pubTimestamp":1788228975,"startTime":"0","endTime":"0","summary":"七月以来，A股生物医药板块迅速走强。与前几次创新药一枝独秀不同，本轮行情呈现创新药与CXO“双星闪耀”态势，多只个股创近五年股价新高。这得益于企业基本面改善、估值修复、地缘风险缓释及政策利好的叠加。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609013861234285.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609013861234285.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0010","03069","BK0175","BK0082","BK0250","BK0185","BK0028","BK0188","600056"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663280750","title":"新股消息 | 贝达药业(300558.SZ)再度递表港交所 “四驾马车”协同打造全产业链生物制药","url":"https://stock-news.laohu8.com/highlight/detail?id=2663280750","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663280750?lang=zh_cn&edition=full","pubTime":"2026-08-31 08:14","pubTimestamp":1788135285,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["03069"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663043115","title":"每周股票复盘：中国医药（600056）股东户数下降3.43%，中报净利降15.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663043115","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663043115?lang=zh_cn&edition=full","pubTime":"2026-08-30 08:08","pubTimestamp":1788048497,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，中国医药报收于9.28元，较上周的9.2元上涨0.87%。本周，中国医药8月26日盘中最高价报9.5元。中国医药当前最新总市值138.82亿元，在医药商业板块市值排名6/32，在两市A股市值排名1368/5211。本周关注点股本股东变化：股东户数较上期减少3.43%，户均持股上升至1.2万股。第二季度单季主营收入87.63亿元，同比上升2.51%；单季归母净利润6691.42万元，同比下降44.88%；单季扣非净利润5316.83万元，同比下降43.65%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000004159.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","BK0250","BK0175","BK0082","600056","BK0185","BK0010","03069"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662740312","title":"中国医药（600056）2026年中报简析：净利润同比下降15.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662740312","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662740312?lang=zh_cn&edition=full","pubTime":"2026-08-27 06:02","pubTimestamp":1787781737,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期中国医药发布2026年中报。根据财报显示，中国医药净利润同比下降15.26%。截至本报告期末，公司营业总收入169.52亿元，同比下降0.73%，归母净利润2.49亿元，同比下降15.26%。按单季度数据看，第二季度营业总收入87.63亿元，同比上升2.51%，第二季度归母净利润6691.42万元，同比下降44.88%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700010794.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["03069","600056"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662749516","title":"股市必读：中国医药中报 - 第二季度单季净利润同比下降44.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662749516","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662749516?lang=zh_cn&edition=full","pubTime":"2026-08-27 02:20","pubTimestamp":1787768423,"startTime":"0","endTime":"0","summary":"业绩披露要点：2026年第二季度单季度归母净利润6691.42万元，同比下降44.88%。业绩披露要点财务报告2026年中报显示，上半年度主营收入169.52亿元，同比下降0.73%；归母净利润2.49亿元，同比下降15.26%；扣非净利润2.31亿元，同比下降9.81%；第二季度单季度主营收入87.63亿元，同比上升2.51%；单季度归母净利润6691.42万元，同比下降44.88%；单季度扣非净利润5316.83万元，同比下降43.65%；负债率62.69%，投资收益1252.66万元，财务费用1.25亿元，毛利率10.86%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700006817.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600056","03069"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662465759","title":"图解中国医药中报：第二季度单季净利润同比下降44.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662465759","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662465759?lang=zh_cn&edition=full","pubTime":"2026-08-26 01:40","pubTimestamp":1787679645,"startTime":"0","endTime":"0","summary":"证券之星消息，中国医药2026年中报显示，上半年度公司主营收入169.52亿元，同比下降0.73%；归母净利润2.49亿元，同比下降15.26%；扣非净利润2.31亿元，同比下降9.81%；其中2026年第二季度，公司单季度主营收入87.63亿元，同比上升2.51%；单季度归母净利润6691.42万元，同比下降44.88%；单季度扣非净利润5316.83万元，同比下降43.65%；负债率62.69%，投资收益1252.66万元，财务费用1.25亿元，毛利率10.86%。财报数据概要请见下图:本文数据来源于中国医药2026年中报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600004235.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600056","03069"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661643312","title":"步长制药：注射用艾帕依泊汀α为公司子公司四川泸州步长生物制药有限公司自主研发的治疗用生物制品1类新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2661643312","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661643312?lang=zh_cn&edition=full","pubTime":"2026-08-21 18:15","pubTimestamp":1787307315,"startTime":"0","endTime":"0","summary":"投资者提问：2026年07月28日药品通知件送达信息显示注射用艾帕依泊汀α未通过审批，请问公司创新药是自研还是合作模式？注射用艾帕依泊汀α为公司子公司四川泸州步长生物制药有限公司自主研发的治疗用生物制品1类新药。因该药品需进一步完善申报资料，经与国家药品审评中心沟通后，决定撤回注册申请，待完善相关资料后择期重新提交药品上市许可注册申请。截至目前该品种仍处于研发阶段，尚未纳入国家医保药品目录。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100033843.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603858","BK0239","BK0196","03069"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124447538","title":"港股生物科技股大涨，思路迪医药股份涨超80%，云顶新耀涨超60%","url":"https://stock-news.laohu8.com/highlight/detail?id=1124447538","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124447538?lang=zh_cn&edition=full","pubTime":"2026-08-20 09:30","pubTimestamp":1787189405,"startTime":"0","endTime":"0","summary":"8月20日，港股$生物(000504)$科技股大涨，$思路迪医药股份(01244)$涨超80%，$云顶新耀(01952)$涨超60%，$康希诺生物(06185)$涨超50%，$艾美疫苗(06660)$涨超45%，$剂泰科技-P(07666)$涨超25%，$科济药业-B(02171)$涨超7%。","market":"hk","thumbnail":"https://static.tigerbbs.com/424a61980d8d04f8172cdf5eafb309c0","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/424a61980d8d04f8172cdf5eafb309c0"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VGT","BK1161","09834","BK4585","03069","09086","BK1191","07266","02834","BK1585","07261","01952","06660","BK1574","BK4588","BK1583","BK1515","XLK","07666","02171","03034","01244","BK1147","03086","07568","07522","KCAI","VXUS","03455","06185","BK1587","TTTN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660491288","title":"股市必读：中国医药（600056）8月18日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2660491288","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660491288?lang=zh_cn&edition=full","pubTime":"2026-08-19 02:55","pubTimestamp":1787079311,"startTime":"0","endTime":"0","summary":"截至2026年8月18日收盘，中国医药报收于9.44元，下跌0.63%，换手率0.88%，成交量13.22万手，成交额1.25亿元。董秘最新回复投资者： 要推动科技创新成果在卫生健康领域转化运用，推进全民健康数智化建设。请问公司在科技创新和健康数智化建设做了什么工作董秘： 您好！公司将结合自身业务实际，稳步推动科技创新成果转化与数智化转型升级。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900001998.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","03069","BK0175","BK0082","BK0250","BK0185","BK0028","BK0188","600056"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0637},{"period":"1month","weight":-0.036},{"period":"3month","weight":0.2061},{"period":"6month","weight":0.0654},{"period":"1year","weight":-0.1327},{"period":"ytd","weight":0.0439}],"compareEarnings":[{"period":"1week","weight":-0.033},{"period":"1month","weight":-0.0249},{"period":"3month","weight":0.0035},{"period":"6month","weight":-0.0259},{"period":"1year","weight":-0.0491},{"period":"ytd","weight":-0.0322}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.040155},{"month":2,"riseRate":0.4,"avgChangeRate":0.03003},{"month":3,"riseRate":0.2,"avgChangeRate":-0.029137},{"month":4,"riseRate":0.833333,"avgChangeRate":0.013346},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.016542},{"month":6,"riseRate":0.5,"avgChangeRate":0.022933},{"month":7,"riseRate":0.666667,"avgChangeRate":0.035744},{"month":8,"riseRate":0.5,"avgChangeRate":-0.011048},{"month":9,"riseRate":0.333333,"avgChangeRate":0.014238},{"month":10,"riseRate":0.2,"avgChangeRate":-0.044379},{"month":11,"riseRate":0.6,"avgChangeRate":0.051035},{"month":12,"riseRate":0.2,"avgChangeRate":-0.056464}],"exchange":"SEHK","name":"华夏恒生生科","nameEN":"CAM HSBIOTECH"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华夏恒生生科(03069)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华夏恒生生科(03069)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华夏恒生生科,03069,华夏恒生生科股票,华夏恒生生科股票老虎,华夏恒生生科股票老虎国际,华夏恒生生科行情,华夏恒生生科股票行情,华夏恒生生科股价,华夏恒生生科股市,华夏恒生生科股票价格,华夏恒生生科股票交易,华夏恒生生科股票购买,华夏恒生生科股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华夏恒生生科(03069)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华夏恒生生科(03069)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}